



Trends In Treatment Product Use And Expenditure In Australia

Alison Turner
National Blood Authority
CEO & GM

10 October 2009

Saving & improving Australian lives through a world-class blood supply


Haemophilia Treatment Centres in Australia



- 🔴 18* HTC Australia wide
- 🔴 898 unique patients identified in ABDR 2009**
- 🔴 Haemophilia A patients 637
- 🔴 Haemophilia B patients 140
- 🔴 Others (vWD, platelet disorder, other factor deficiencies) 121

Total Blood Expenditure

🩸 Clotting factor products are almost a quarter of funding or \$181m allocated by jurisdictions across all blood products in 2008 - 09



The Cost Of Product



Prophylactic treatment for haemophilia A (rFVIII)
35 IU/KG, 3 times per week for 70kg male


= 7,350IU per week
=382,200 IU per year



Annual cost of product:
\$301,938




The Cost Of Product




Growth In Issue Of Products

🔴 Increase and split of Factor VIII between 2003 - 09



Usage Per Population


🔴 Issue of Factor VIII per 1,000 population



Treatment Usage Trends

- 🔴 Usage by population throughout the world*


Total Factor VIII: IU ('000) per 1000 capita



* Presentation to the NBA by **Jan M. Bult President PPTA**. Canberra, Nov 10 2008


Growth In Issue Of Products

🔴 Increase and split of Factor IX between 2003 - 09



Usage Per Population

🔴 Issue of Factor IX per 1,000 population



Government Focus- safe, appropriate, secure, affordable

- 🔴 Worlds best practice
 - In country reserves
 - Latest generation of products
 - Contract protections
 - Preferred customer status
 - ABDR

- 🔴 Worlds best price
 - Minimal increase since 2006, less than C.P.I.
 - Competitive market focus of suppliers

Patients Focus- support affordability and appropriate.

- 🔴 Vigilant care of product-
 - No wastage
 - Appropriate storage including cold chain integrity
 - No unnecessary inventories

- 🔴 Accountability of use
 - Every IU should be clinically vital
 - Appropriate dose, round down and monitor
 - Maintain your health

**The government has
demonstrated a high
commitment to treating
Haemophilia**

**Patients have a key
responsibility as partners**